Crossmark

Ustekinumab in the Management of Perianal Fistulizing Crohn’s Disease: Current Evidence and Practical Strategies

Published Online: 2026-05-22

Published Print: 2026-06

Authors

Yang, Bolin
Funding

Funding for this research was provided by:

Johnson & Johnson Innovative Medicine
License Information

Text and Data Mining valid from 2026-05-22

Version of Record valid from 2026-05-22
More Information

Article History

Received: 12 September 2025

Accepted: 28 April 2026

First Online: 22 May 2026

Declarations

Conflicts of Interest: Bolin Yang has no conflicts to disclose.

Ethics Approval: Not applicable.

Consent to Participate: Note applicable.

Consent for Publication: Not applicable.

Document is current